CytRx (CYTR) Selects DK049 for Development
Tweet Send to a Friend
CytRx Corporation (Nasdaq: CYTR) announced that it has selected its next drug, designated DK049, for clinical development in 2016 ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE